Alethia Biotherapeutics secures CAD9.6m led by AgeChem, BDC and GO
Alethia Biotherapeutics, a Montreal-based biopharmaceutical company focused on the development of monoclonal antibodies, has closed a CAD9.6m series A round of financing. Alethia will use the proceeds to advance its lead pre-clinical programmes into clinical development over the next 18 months. Co-led by AgeChem Venture Fund and existing investor BDC
